DOI:
10.1055/s-00046370
Global Medical Genetics
LinksClose Window
References
Yan X, Lin Z, Lifang Z, Yingchun W, Mei W, Zhenfan Y.
DZD9008, an oral, wild type selective EGFR inhibitor for the treatment of non-small-cell lung cancer with Exon20 insertion and other activating mutations.
Cancer Res 2019;
DOI: 10.1158/1538-7445.AM2019-3081.
Access:
We do not assume any responsibility for the contents of the web pages of other providers.